3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-10-09NCT04055493
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSNeoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, female breast carcinoma, neoplasm, skin disorderRecruitingNot stated2026-08-05NCT05792150
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaRecruitingPhase 32026-08-03NCT06081244